Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials

Related Experiment Video

Updated: Jul 17, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Jan Pecenak1

  • 1Department of Psychiatry, University Hospital Bratislava, Slovakia. jan.pecenak@faneba.sk

Neuro Endocrinology Letters
|January 31, 2007
PubMed

Insights

This review examines long-term studies comparing second-generation antipsychotics (SGAs) to other treatments. It highlights methodological issues and factors affecting clinical trial outcomes for SGAs.

Area of Science:

  • Psychiatry and Pharmacology
  • Clinical Trial Analysis

Background:

  • Second-generation antipsychotics (SGAs) are widely used for psychiatric conditions.
  • Evidence on long-term efficacy and safety requires thorough evaluation.

Purpose of the Study:

  • To review and synthesize findings from long-term randomized controlled trials of SGAs.
  • To critically assess methodological aspects influencing study outcomes.

Main Methods:

  • Systematic review of 14 double-blind, randomized studies published after 2002.
  • Studies compared SGAs against placebo, conventional antipsychotics, or other SGAs.
  • Focus on trials with a minimum duration of 26 months.

Main Results:

  • Summarizes comparative efficacy and safety data from long-term SGA trials.
  • Discusses variability in results attributed to patient populations, outcome measures, and drug dosages.
  • Identifies common methodological challenges in SGA research.

Conclusions:

  • Long-term comparative data on SGAs is crucial for clinical decision-making.
  • Methodological rigor is essential for reliable SGA research.
  • Understanding influencing factors can optimize the interpretation of SGA trial results.

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...